Opisanie klinicheskikhsluchaev primeneniya kombinatsiys lapatinibom v lecheniiHER2-pozitivnogo rasprostranennogoraka molochnoy zhelezy


Cite item

Full Text

Abstract

References

  1. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82.
  2. Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
  3. Tripathy D, Slamon DJ et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-70.
  4. Montemurro F, Donadio M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncolog 2006; 11: 318-24.
  5. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
  6. Spector NL, Xia W et al. Study of the biological effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-12.
  7. Jackisch C. HER2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncolog 2006; 11 (Suppl. 1): 34-41.
  8. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
  9. Gomez HL. A randomized open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment GLICO-0801. ASCO Ann Meeting. J Clin Oncol 2010; 28 (Suppl.): 15. Abstr. TPS120.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964
от 18.12.2015 г.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies